Insider Transactions in Q4 2020 at Fibrogen Inc (FGEN)
Insider Transaction List (Q4 2020)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 28
2020
|
Kalevi Kurkijarvi Director |
SELL
Open market or private sale
|
Direct |
6,001
-7.7%
|
$240,040
$40.76 P/Share
|
|
Dec 28
2020
|
Kalevi Kurkijarvi Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6,001
+6.65%
|
$108,018
$18.7 P/Share
|
|
Dec 16
2020
|
K Peony Yu Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,350
-1.71%
|
$137,350
$41.61 P/Share
|
|
Dec 15
2020
|
Pat Cotroneo Executive Advisor & Former CFO |
SELL
Open market or private sale
|
Direct |
3,068
-1.14%
|
$131,924
$43.6 P/Share
|
|
Dec 07
2020
|
Christine Chung SVP, CHINA OPERATIONS |
SELL
Payment of exercise price or tax liability
|
Direct |
3,039
-1.98%
|
$124,599
$41.99 P/Share
|
|
Dec 07
2020
|
Pat Cotroneo Executive Advisor & Former CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,014
-1.11%
|
$123,574
$41.99 P/Share
|
|
Dec 07
2020
|
Elias Kouchakji SVP, Clinical Dev, Drug Safety |
SELL
Payment of exercise price or tax liability
|
Direct |
2,728
-2.03%
|
$111,848
$41.99 P/Share
|
|
Dec 07
2020
|
K Peony Yu Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,292
-1.65%
|
$134,972
$41.99 P/Share
|
|
Dec 01
2020
|
Mark Eisner EVP, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+50.0%
|
-
|
|
Nov 17
2020
|
Elias Kouchakji SVP, Clinical Dev, Drug Safety |
BUY
Exercise of conversion of derivative security
|
Direct |
7,082
+5.0%
|
$99,148
$14.57 P/Share
|